Clinical Scorecard: Strategic Development of Live Biotherapeutic Products to Prevent Clostridioides difficile Infections
At a Glance
Category
Detail
Condition
Clostridioides difficile infection (CDI), a major cause of healthcare- and antibiotic-associated diarrhea
Key Mechanisms
Disruption of gut microbiome by antibiotics leading to CDI; restoration of colonization resistance via fecal microbiota transplantation (FMT) or live biotherapeutic products (LBPs)
Target Population
Patients with primary or recurrent CDI, particularly adults 18 years and older
Care Setting
Healthcare settings including hospitals and outpatient clinics managing CDI
Key Highlights
CDI affects approximately 500,000 patients annually in the US with about 30,000 deaths.
Antibiotics are standard treatment but have a 25% recurrence rate and contribute to CDI risk.
Live biotherapeutic products (LBPs) using defined bacterial consortia are a promising alternative to FMT for preventing recurrent CDI.
Guideline-Based Recommendations
Diagnosis
Use metagenomic sequencing and strain-level microbial profiling to identify CDI-related microbial strains.
Employ whole metagenome shotgun sequencing and metagenome-assembled genomes (MAGs) for detailed microbiome analysis.
Management
Standard antibiotic therapy for primary CDI.
Consider fecal microbiota transplantation (FMT) for recurrent CDI, noting potential risks of pathogen transmission.
Use FDA-approved fecal microbiota products (e.g., Rebyota, Vowst) post-antibiotic treatment to prevent rCDI in adults.
Develop and apply live biotherapeutic products (LBPs) with predefined bacterial consortia targeting CDI.
Monitoring & Follow-up
Monitor for CDI recurrence post-antibiotic therapy.
Assess microbial strain engraftment and microbiome restoration following FMT or LBP administration.
Risks
Antibiotic use increases risk of CDI and recurrence.
FMT may transmit undetected or emerging pathogens.
Emergence of C difficile strains with decreased antibiotic sensitivity.
Patient & Prescribing Data
Adults 18 years and older with recurrent CDI following antibiotic treatment
FDA-approved fecal microbiota products show modest to robust effect sizes in preventing rCDI; microbial composition and ecological rationale vary between products.
Clinical Best Practices
Employ computational frameworks and metagenomic data to rationally design LBPs targeting CDI.
Use strain-level microbial analysis to select protective bacterial strains for LBPs.
Prefer defined bacterial consortia over undefined donor stool to reduce safety risks.
Incorporate multiple metagenomic binning tools and quality control measures to reconstruct high-quality MAGs for microbiome characterization.
